Venetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1
Clinical Trials Related to Obinutuzumab
Related studies linked through entity extraction aliases.
A Prospective Cohort of Obinutuzumab and Chlorambucil (GC) Chemotherapy for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia Including Next- Generation Sequencing (NGS)-Based Assessment
- Status
- UNKNOWN
- Phase
- PHASE2
Untreated FolliculaR Lymphoma Treated With OBinituzumAb in a Non-interventional Study (URBAN)
- Status
- COMPLETED
- Phase
- N/A
FT516 in Subjects With Advanced Hematologic Malignancies
- Status
- TERMINATED
- Phase
- PHASE1
Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma
- Status
- TERMINATED
- Phase
- PHASE1
Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- Status
- RECRUITING
- Phase
- PHASE2
An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma
- Status
- COMPLETED
- Phase
- PHASE4
Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients with Relapsed/refractory CLL
- Status
- COMPLETED
- Phase
- PHASE2
Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia
- Status
- TERMINATED
- Phase
- PHASE1
Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1